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Recent studies by Lawrence et al.  (1) have provided evidence for polymorpho- 
nuclear  leukocyte  receptors  capable  of binding IgA.  In addition,  our previous 
studies have described the presence  of circulating  IgA-associated  inhibitors of 
leukocyte chemotaxis in patients with liver disease (2). Elevation in concentra- 
tion of serum IgA  is  a  common occurrence  in patients  with  various forms of 
subacute or chronic liver disease  (3,  4); moreover,  our studies have suggested 
some parallel between degrees of serum chemotactic inhibitory activity  (CIA) ~ 
and quantitative  estimations  of serum IgA.  The  present  study was  aimed  at 
examining the influence of serum and isolated M components from patients with 
IgA myeloma on leukocyte chemotaxis in vitro. It would appear that IgA may in 
some way directly  affect leukocyte  chemotaxis possibly by steric  hindrance  of 
chemotactic receptors or by other cell-associated modulating influences. 
Materials and Methods 
Cell Preparation,  Chemotaxis,  and Random Mobility.  Human polymorphonuclear leukocytes 
(PMNs)  were  prepared from  peripheral blood of healthy  adult  donors.  Blood was  mixed  with 
heparin,  10 U/ml, to prevent coagulation.  Neutrophil preparations were obtained as previously 
described (2, 5-7) by Plasmagel sedimentation of erythrocytes and resuspension of leukocytes to a 
concentration of 7  x  106 PMNs/ml in Hanks' balanced salt solution (HBSS). In some experiments 
mononuclear cells were removed from these preparations by Ficoll-Hypaque centrifugation (8). 
Cell suspensions obtained by this combined technique contained greater than 95% PMNs.  Mono- 
cytos were prepared by Ficoll-Hypaque centrifugation of whole blood (8), and the band ofmononu- 
clear cells was collected, washed, and adjusted to a cell concentration of 5  x  l0  s cells per ml with 
HBSS. This preparation contained from 11 to 40% monocytes as determined by peroxidase staining 
(9). 
Studies  of PMN  chemotaxis  were  performed  using  a  modified  Boyden  technique  (2,  5-7). 
Chemotaxis was expressed as a  chemotactic index representing the average number of cells per 
high power  field  (400  ×)  which had  migrated  to  the  distal  side  of the  membrane.  Monocyte 
chemotaxis was measured in a similar type of chamber with a 5 fern pore size Nuclepore membrane 
(Nuclepore Corp., Pleasanton, Calif.) (10).  In some PMN experiments a slightly different Boyden 
type chamber was used (11) so that the lower compartment could be aspirated and the number of 
cells which had migrated into the lower chamber counted. 
Random PMN mobility was assessed using the capillary tube migration assay (12). PMNs were 
isolated  by  combined  plasmagel  sedimentation  and  Ficoll-Hypaque  centrifugation.  Capillary 
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tubes were incubated in  chambers containing minimum essential  medium [Eagle]  (MEM) supple- 
mented with  5% fetal  calf  serum. The index  of  random mobility  was the product in  millimeters  of 
the  two  axes  of  the  developing cell  flare.  The  index  for  control  cells  ranged  from  7.5  to  16  depending 
on the donor. 
Chemotactic  factors  used  in  this  study  consisted  of  a 10% solution  of  fresh  normal  human serum 
(NS), a 10% solution  of  culture supernate from a 24-h culture  of  Escherichia coli (strain  K  12) 
grown in MEM  and referred  to as bacterial  factor  (BF),  a 20% solution  of  casein-saturated  MEM 
(approximately 2 mg/ml) (7),  and purified  C5a (13).  In each case as specified,  test  samples were 
added  either  to  the  upper  or  lower  compartment  of  the  chemotaxis  chamber. Resulting  chemotaxis 
toward a control  chemotactic attractant  in the presence of  the test  sample was compared to that 
obtained with only the control chemotactic  attractant.  The effects  of the test  sample were 
expressed as a percent of  the control.  The mean chemotactic index for each of  the chemotactic 
factors used was as follows: NS = 81 +- 31; BF = 76 +__ 37; casein = 83 -+ 17. These indices are in the 
optimum range for detection of effects on chemotaxis in this system. 
Testing of Sera, M Components, and Colostral IgA.  Whole sera from patients with IgG and 
IgA myeloma, as well as sera from patients with WaldenstrSm's macroglobulinemia, were tested 
for inhibition  in chemotaxis assays before  and after  heat treatment at 56°C for 30 min. This 
treatment  has previously  been shown to  enhance CIA in  various test  sera,  possibly  as a result  of 
aggregation of  inhibitors  or inactivation  of  inhibitor  antagonists (7). 
IgA M  components were prepared from the sera of patients with IgA myeloma containing 
greater  than 1,500  mg/100 ml IgA  by a combination  of  starch  block  electrophoresis  and DEAE  ion 
exchange chromatography (14).  In some cases IgA preparations were further fractionated  over 
Sephadex G-200 gel equilibrated  with pH 7.4 phosphate-buffered saline (PBS) or by passage 
through an insolubilized  anti-lgG immunoadsorbent column f15).  Immunoelectrophoresis  of  iso- 
lated  IgA M  components showed only a single  precipitin  band corresponding to IgA with anti- 
whole  human serum. No  reactions  were  noted  with  several  antisera  to  IgG. Several IgA  myelomas 
which  had  been  previously  typed  as  IgAt  or  IgA2  were  provided  by  Doctors H. G. Kunkel, H. Grey, 
R. Wistar, and H. Spiegelberg.  Preparations of  purified  human colostral  IgA were obtained from 
pooled human colostrum (16). 
Serum concentrations of IgA were determined using the Oudin tube technique (17).  When 
isolated  preparations  of  IgA were used,  the concentrations  were determined  by  optical  density at 
280 nm or  by the Folin  reaction  (18). 
Immunoadsorbent Columns.  Insolubilized immunoadsorbent columns were prepared by cyan- 
ogen bromide conjugation of either rabbit anti-IgG or anti-IgA to sepharose (15). 
Ultracentrifugation.  Ultracentrifugation for removal of large immunoglobulin complexes was 
achieved using  a  Beckman  preparative  model L  ultracentrifuge  and  centrifugation  (Beckman 
Instruments,  Inc., Fullerton, Calif.) at 100,000 g  for a period of 11/2 h. 
5-20%  sucrose  density gradient centrifugation  of whole serum was performed as previously 
described (2) using an SW-50.1 swinging bucket rotor and centrifuging at 100,000 g  for 15 h. In 
some cases 0.2 ml of isolated IgA preparations  (8-10 mg/ml) were separated on 7-ml gradients 
using a SW 41 swinging bucket rotor and 18 h of centrifugation at 100,000 g. After centrifugation, 
0.3-ml fractions were collected from the bottom, dialyzed against PBS, and tested for CIA. 
Pepsin Digestion oflgA.  IgA (10 mg/ml) was incubated at 37°C with pepsin (2% by weight) at 
pH 4.1 (0.1 M acetate) for 18 h (19). The sample was then dialyzed against PBS or passed through a 
Sephadex  G-200  column  equilibrated  with  PBS.  Eluted  protein  peaks  were  concentrated  to 
original volume. Each preparation was assayed for IgA or IgA fragments by Ouchterlony immuno- 
diffusion analysis and found to be devoid of Fc antigenic determinants. 
Reductmn and Alkylation of IgA M Components.  Isolated IgA M components  (8-10 mg/ml) 
were reduced with dithiothreitol (DTT) (0.01 M) for 1 h at 37°C, alkylated for 15 rain in the dark at 
room temperature with 0.033  M iodoacetamide (20), and analyzed by polyacrylamide gel electro- 
phoresis (21). 
Results 
Effects of Sera from Patients with IgG Myeloma, IgA Myeloma, or Walden- 
strain's  Macroglobulinemia  on Normal PMN Chemotaxis.  12  sera  from  pa- 
tients  with  IgG  myeloma,  24  patients  with  IgA myeloma,  and  5  patients  with DENNIS  E.  VAN  EPPS  AND  RALPH  C.  WILLIAMS  Jr.  1229 
WaldenstrSm's macroglobulinemia were tested before and after a 56°C, 30-rain 
heat treatment for their effects on normal PMN chemotaxis toward 10% fresh 
normal serum. The test sample consisted of a mixture of 10% normal serum and 
10% patient serum. No general suppression of PMN chemotaxis was observed 
when IgG myeloma or Waldenstr6m's macroglobulinemia sera were tested (Fig. 
1).  However,  when 24  IgA myeloma sera  were  tested in  a  similar manner, 
inhibition was observed with the majority of samples before heat treatment and 
in all but three samples after 56°C heat treatment. The mean effect of the IgA 
myeloma sera before heat treatment was a 43% suppression of chemotaxis and 
71% inhibition after heat treatment. This suppression occurred with both PMN 
preparations  obtained by plasmagel  sedimentation of erythrocytes that  con- 
tained mononuclear cells and PMN preparations obtained by a combination of 
plasmagel sedimentation followed by Ficoll-Hypaque centrifugation to remove 
mononuclear cells. There was no apparent association between serum concen- 
trations of IgA or IgA subclasses or light chain type and the degree of chemotac- 
tic  inhibition  (Table  I).  These  experiments  were  reproduced  in  a  modified 
version of the Boyden chemotaxis chamber which allows aspiration of the lower 
compartment fluid (11), so that PMNs which may fall off the lower side of the 
membrane could be  quantitated.  Results indicated that the number of cells 
found in the lower compartment were greatly reduced when IgA myeloma sera 
were added to the chemotaxis system. Thus, reduced adherence of PMNs to the 
lower side of  the membrane was not responsible for the observed reduction in the 
chemotactic index. 
Suppression  of Casein  and  BF-Medicated  Chemotaxis  by  IgA  Myeloma 
Sera.  10 IgG myeloma sera, 7 IgA myeloma sera, and 4 WaldenstrSm's mac- 
roglobulinemia sera were tested simultaneously with respect to their effect on 
chemotaxis mediated by NS, casein, and BF. Fig. 2 shows that although no CIA 
was observed in IgG myeloma samples when NS was used as  a  chemotactic 
attractant,  some suppression was observed when BF or casein were used as 
chemotactic attractants. The mean inhibition was 25% for tests using BF and 
14% for tests using casein. Although some inhibitory activity was found in IgG 
myeloma samples, this didnot compare to that found in IgA myeloma samples 
in degree or in frequency. The mean inhibitory activity observed with the seven 
IgA myeloma sera was 75% when NS was used as a chemotactic attractant, and 
78% and 77% when BF and casein were used as chemotactic attractants. One of 
these IgA myeloma samples failed to suppress NS-mediated chemotaxis. This 
lack of  CIA was consistent with all three chemotactic factors. The suppression of 
chemotaxis by IgA myeloma sera was nonspecific with respect to chemotactic 
attractants  since  inhibition was  of the  same  order  of magnitude with  each 
chemotactic factor. 
Effects  of Isolated  IgA M Components  and Colostral IgA on PMN Chemo- 
taxis.  Because CIA appeared to be  most pronounced in IgA myeloma sera, 
isolated IgA myeloma components were added to the 0.4 ml upper compartment 
of the chemotaxis chamber and titrated with respect to suppression of PMN 
chemotaxis. Suppression was observed at concentrations as low as 0.0625 mg of 
the isolated M component, and inhibition was independent of the chemotactic 
factor used (Fig. 3). A total of 11 isolated IgA M components including the two 
shown in Fig. 3 and 1 pooled human colostral IgA preparation were tested both 1230  SUPPRESSION  OF  CHEMOTAXIS  BY  HUMAN  IgA  MYELOMA  COMPONENTS 
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FIG,  1.  Effects of IgG and IgA myeloma sera and Waldenstrom's macroglobulinemia sera 
on PMN chemotaxis toward fresh NS.  Results indicate effect before and after 56°C heat 
treatment of the test sample. 
before and after a 30 min, 56°C heat treatment with respect to PMN CIA (Fig. 4). 
This heat treatment tended to enhance the observed CIA. Both isolated IgA M 
components  and  isolated  human  colostral  IgA  effectively suppressed  PMN 
chemotaxis, indicating that IgA-mediated suppression of chemotaxis was not 
associated solely with myeloma IgA.  Four of the isolated IgA M  components 
were also tested in a  PMN chemotactic system mediated by purified C5a and 
similar suppression  was  recorded.  Tests  using similar concentrations of two 
preparations of pooled human IgG (human fraction II) and three isolated IgG M 
components resulted in a mean inhibition of 28 _+ 7% before heat treatment and 
23  _  13% after heat treatment. This inhibitory activity was significantly less 
than that observed with IgA preparations (mean inhibition =  59  _+ 36% before 
heat treatment and 83  -  28% after heat treatment). 
Effects  of IgA Myeloma  Serum, Isolated IgA M Components,  and Colostral 
IgA on Monocyte Chemotaxis.  Table II shows the comparative results of mono- 
cyte and PMN chemotaxis experiments where 0.1 ml of heat-treated IgA mye- 
loma serum or I mg of isolated IgA M component or colostral IgA were added to 
the upper compartment of the Boyden type chamber. Very little suppression of 
monocyte chemotaxis was observed when whole myeloma sera were used, and 
partial suppression of monocyte chemotaxis was observed when isolated compo- 
nents were used. 
Loss  of CIA  After Absorption  of IgA  by  Specific  Immunoadsorbent  Col- 
umns.  0.5-ml samples containing 6 mg of isolated IgA from two patients with 
demonstrable CIA were passed through a Sepharose anti-IgA immunoadsorbent 
column, fluted fractions were concentrated to original volume dialyzed against 
HBSS and tested for CIA both before and after a 56°C., 30 min heat treatment. 
No  IgA  was  present  in  these  fractions  as  determined  by  immunodiffusion 
analysis nor was CIA observed. DENNIS  E.  VAN  EPPS  AND  RALPH  C.  WILLIAMS  Jr.  1231 
TABLE  I 
Effects of Serum from Patients with IgA Myeloma on Normal PMN Chemotaxis 
Test* serum  Myeloma sub-  Light  IgA concen- 
sample  class  chain class  tration 
Inhibition of chemotaxis 
Before heat  After heat 
treatment  treatment 
mg/lO0 ml  % 
IgA myeloma 
1  -  -  2,500  34  98 
2  -  K  1,480  66  93 
3  -  ~  1,700  78  74 
4  -  h  1,580  0  0 
5  -  K  2,250  18  62 
6  -  -  2,220  74  94 
7  IgA,  K  1,280  87  95 
8  -  ~  1,750  79  99 
9  IgA1  h  2,200  49  99 
10  IgA,  K  1,720  0  3 
11  IgA,  K  1,500  33  98 
12  -  K  4,100  0  94 
13  IgA,  h  1,330  97  98 
14  IgA,  h  2,320  76  92 
15  IgA,  K  2,780  94  92 
16  IgA,  K  2,320  2  82 
17  IgA]  K  1,480  0  31 
18  IgA2  K  1,800  58  71 
19  IgA~  k  1,030  2  42 
20  -  k  1,950  74  83 
21  -  K  2,140  5  85 
22  IgAl  K  1,950  98  99 
23  IgA~  K  1,450  0  0 
24  IgA2  K  1,370  0  22 
Average 43  71 
* In each case 10% fresh NS was used as a control chemotactic attractant  and the test sample 
consisted of a mixture of 10% fresh human serum and 10% untreated or heat-treated (56°C 30 
min) patient serum. 
Site ofIgA Chemotactic Suppression.  Experiments were conducted to deter- 
mine if the observed suppression of PMN chemotaxis was due to a  direct cellular 
effect.  PMNs  (5.6  ×  10  s)  were  incubated  for  15  min  at  37°C  in  0.5  ml  of a 
preparation  of isolated IgA M  component  (2  mg/ml).  Cells were washed  twice 
and  tested  for  their  chemotactic  responsiveness.  Controls  consisted  of  cells 
treated  similarly  with  PBS  and  tested  in  the  presence  or  absence  of IgA  M 
component.  Preincubation  of PMNs  with two  isolated IgA M  components and 
subsequent washing resulted in a  84 and 100% suppression of chemotaxis, while 
the direct addition of the M  component to the chemotaxis chamber resulted in a 
92 and 100% inhibition of chemotaxis, respectively. These data support a  cellular 
mode  of chemotactic  inhibition.  In  additional  experiments  this  cell-directed 
inhibition of PMN  chemotaxis was found to be partially reversible after a  3-h 
subsequent  incubation  of PMNs  in  MEM  supplemented  with  5%  heat-inacti- 
vated fetal calf serum  as shown in Fig. 5. 
Effect  of IgA  M  Component  on  PMN  Random  Mobility.  PMN  random 1232  SUPPRESSION  OF  CHEMOTAXIS  BY  HUMAN  IgA  MYELOMA  COMPONENTS 
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Effect of IgG and IgA myeloma sera and WaldenstrSm's macroglobulinemia sera 
on PMN chemotaxis toward human serum (NS), bacterial-derived chemotactic factor (BF), 
and  casein  (Cas).  Test  samples were  heat  treated  (56°C for  30  min)  and  used  at  10% 
concentrations in the lower compartment of  the chemotaxis chamber with each chemotactic 
factor. 
mobility was assayed by the capillary tube migration  technique  (12).  In each 
case capillaries  containing  PMNs were fixed into chambers  and incubated  in 
control medium or medium containing  1 mg/ml of isolated IgA M  component. 
The results in Table III show that in three cases (IgA's no. 2, 3,  and 6) partial 
suppression of random mobility was observed although the degree of inhibition 
was much less than the suppression of PMN chemotaxis, while in two cases IgA 
samples with greater than 80% CIA failed to suppress random mobility. 
Physical Studies 
ULTRACENTRIFUGATION  AND  SUCROSE  DENSITY  GRADIENT  CENTRIFUGA- 
TION.  Since heat treatment resulted in enhanced CIA, it was postulated that 
aggregates  of IgA may interact  with the PMN-IgA receptor  (1) and result  in 
chemotactic suppression much like that mediated by immune complexes (22). 
Two IgA myeloma serum samples were centrifuged  at  100,000 g  for 11/2 h  to 
remove any large aggregates of IgA that might exist in these samples. Tests of 
these  samples  following this  procedure  indicated  that  CIA  remained  in  the 
supernate,  while the small 0.2 ml pellet of material  at the bottom of the tube 
showed no CIA. 
IgA myeloma serum samples  and  M  components were separated by 5-20% 
sucrose density gradient centrifugation,  and gradient fractions were tested for 
CIA. As shown in Fig. 6 A, B, and C the majority of inhibitory activity in three 
different IgA myeloma sera was found to sediment within the 10S to 14S region 
as compared to the 7S human IgG marker.  However, some inhibitory activity 
was also found in the 7S to 8S region in certain samples. DENNIS  E.  VAN  EPPS  AND  RALPH  C.  WILLIAMS  Jr.  1233 
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FIG.  3.  Titration of isolated IgA M components with respect to inhibitory effects on BF- 
mediated PMN chemotaxis (---) and NS-mediated PMN chemotaxis (--). The control chemo- 
tactic indices for NS-mediated chemotaxis were 68 and 73 and for BF-mediated chemotaxis 
were 102 and 40. 
In addition,  isolated IgA M  components from three  different patients  were 
centrifuged on 5-20% sucrose density gradients  (Fig.  6D,  E,  and F).  0.1 ml of 
each gradient fraction was added to the upper compartment of duplicate Boyden 
chambers and tested for its effect on PMN chemotaxis toward fresh NS. Multiple 
peaks of CIA were found in fractions sedimenting between 7S and 13S, Fig. 6 B, 
in regions where polymeric forms of IgA would be expected to sediment. 
EFFECTS  OF PEPSIN TREATMENT  AND DTT REDUCTION  AND ALKYLATION ON  IgA 
INHIBITION  OF CHEMOTAXIS.  Pepsin-treated IgA M components (0.5 mg) were 
tested for CIA and compared to control untreated IgA M components subjected to 
similar pH and temperature conditions. Results show that although isolated IgA 
M  components  suppressed  PMN  chemotaxis,  a  substantial  loss  of CIA  was 
observed when these M components were pepsin digested (Table IV, A). Simi- 
larly, when F(ab)2 fragments were isolated by G-200 fractionation,  no CIA was 
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FIG.  4.  Results ofchemotaxis in the presence of  isolated IgA M components (closed circles) 
and pooled human colostral IgA  (open circles). In each case IgA was added to the cell 
compartment and chemotaxis was toward fresh NS. Lines connect the points on the graph 
representing the same sample before and after heat treatment. 
TABLE  II 
Effect of Myeloma and Colostral IgA on Monocyte and PMN Chemotaxis 
Inhibition* of PMN  Inhibitions of mono- 
Sample  chemotaxis  cyte chemotaxis 
%  % 
Exp. A.  Whole IgA myeloma sera 
1  99  19 
2  71  10 
3  92  0 
Exp. B. Isolated IgA M components (1 mg) 
1  81  51 
2  98  18 
3  91  29 
4  93  52 
Colostral IgA (1 mg)  93  44 
Mean -- 90  Mean =  28 
* Inhibition using 10% fresh NS as a  chemotactic attractant. 
$ Inhibition using a mixture of casein and fresh NS as a chemotactic attractant. Control levels for 
Experiment A and B were 75 and 36 monocytes per oil immersion field. 
Four isolated  IgA M  components capable of suppressing PMN chemotaxis 
before heat  treatment  were reduced with  DTT,  alkylated,  and  subsequently 
tested  for  PMN  CIA.  This  treatment  resulted  in  both  a  conversion  of the 
majority of  polymeric IgA to its monomeric form as evidenced by polyacrylamide 
gel electrophoresis and a simultaneous reduction in CIA (Table IV, B). 
EFFECT OF POLYMERIC AND MONOMERIC IgA ON PMN CHEMOTAXIS.  An isolated 
IgA preparation  containing both polymeric and monomeric forms of IgA was DENNIS  E.  VAN  EPPS  AND  RALPH  C.  WILLIAMS  Jr.  1235 
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FIG.  5.  Reversible inhibition of IgA-mediated chemotactic suppression. Results with two 
different IgA M  components using 10% fresh normal serum as a  chemotactic factor are 
shown. The initial control chemotactic indices for each experiment were 86 and 140. These 
control values varied by less than 20% throughout the 3 h of incubation. 
TABLE  III 
Effect of  lgA M Components on PMN Random Mobility as Compared 
to Chemotaxis 
Random* mobility  Inhibition of 
Sample  index  chemotaxis 
% 
Experiment A 
Control  9.0  (0%)  - 
IgA no. 1  9.0  (0%)  0 
IgA no. 2  6.25  (31%)  81 
Experiment B 
Control  7.5  (0%)  - 
IgA no. 3  5 (33%)  98 
IgA no. 4  7.5 (0%)  96 
IgA no. 5  7.5  (0%)  82 
Experiment C 
Control  16 (0%)  - 
IgA no. 6  9 (44%)  93 
* Number in parentheses indicates the percent suppression of random mobil- 
ity. 
fractionated on Sephadex G-200  (Fig.  7).  Fraction 38 containing 0.2  mg/ml of 
protein from the exclusion volume and fraction 46 from the second peak were 
dialyzed against HBSS. 1 ml of fraction 38 was reduced with DTT and alkylated 
with iodoacetamide. Each of the three samples were subsequently assayed by 
polyacrylamide gel electrophoresis. Multiple bands were observed in fraction 38 
which represent various polymeric forms of IgA with one band representing a 







~  o 
iO(:l 
2O 
0  L 
SUPPRESSION  OF  CHEMOTAXIS  BY  HUMAN  IgA  MYELOMA  COMPONENTS 
i  ~  i  L  i 
B  IQG 
¼ 
5Q-- 




C  A  i 
E 
5C-- 






F  [gG 
- 
4°  I 
F FL 
IO 
BOTTOM  TOP  BOTTOM 
FRACllON  NUMBER 
FIG.  6.  Separation  of IgA myeloma  sera  and  isolated  IgA  M  components  by  sucrose 
density  gradient  centrifugation.  Parts  A,  B,  and  C  are results  on whole  IgA myeloma 
serum; parts  D, E,  and F  are results with isolated IgA M components.  Chemotaxis was 
toward 10% fresh normal serum. In each case the position of the 7S IgG marker is indicated. 
sample,  a  single  band  corresponding  to  the  monomeric  form of IgA  was  ob- 
served.  Acrylamide  gel  analysis  of fraction  46 indicated  that  the  majority of 
protein in this fraction was monomeric IgA with a  small amount of polymeric 
IgA carried  over from the  exclusion  volume peak.  These  same samples were 
tested with respect to their effect on PMN chemotaxis.  PMNs (7  ×  106) were 
suspended in either 1 ml of HBSS, fraction 38, fraction 38 reduced and alkylated, 
or fraction 46. Cell preparations were then tested for chemotactic responsiveness 
toward fresh  normal  serum.  Fig.  7 demonstrates  that  fraction  38  containing 
polymeric IgA effectively suppressed PMN chemotaxis. This suppressive activ- 
ity was lost after reduction and alkylation which resulted in a conversion to the 
monomeric form of IgA. Likewise, fraction 46 containing primarily monomeric 
IgA and only small proportions of polymeric IgA failed to inhibit PMN chemo- 
taxis. 
Discussion 
From this  study,  it  is  evident  that  sera  from patients  with  IgA  myeloma 
contain potent suppressors of PMN chemotaxis. CIA was most prominent in the 
IgA  class  of  myeloma  in  systems  using  fresh  NS  since  IgG  myeloma  and 
WaldenstrSm's macroglobulinemia sera generally failed to inhibit PMN chemo- 
taxis either before or after a 56°C heat treatment. Inhibition of PMN chemotaxis 
by IgA myeloma samples was not specific to a  single  chemotactic  factor,  and DENNIS  E.  VAN  EPPS  AND  RALPH  C.  WILLIAMS  Jr.  1237 
TABLE IV 
Effect of Pepsin Digestion and Reduction-Alkylation  on IgA M 
Component Suppression of PMN Chemotaxis 
Sample*  Inhibition of Chemotaxis 
% 
A. Pepsin digestion 
IgA no. 1  66 
IgA no. 1- pepsin digested  30 
IgA no. 2  50 
IgA no. 2 pepsin digested  28 
B. Reduction- alkylation 
IgA no.  1  57 
IgA no. 1 reduced and alkylated  19 
IgA no. 2  47 
IgA no. 2 reduced and alkylated  4 
IgA no. 3  97 
IgA no. 3 reduced and alkylated  0 
IgA no. 4  36 
IgA no. 4 reduced and alkylated  22 
10% normal serum was used as a  chemotactic attractant, and 0.5 mg of 
the IgA preparation  was added to the upper compartment. 
equivalent  inhibition  was  observed  with  NS,  C5a,  BF,  or  casein-mediated 
chemotaxis. Some CIA was noted with whole heat-treated IgG myeloma sera 
when BF or casein were used as chemotactic attractants, but this suppressive 
activity did not compare to that observed in the IgA myeloma samples either in 
degree or frequency. This inhibitory effect may be the result of IgG aggregates 
or the presence of the heat stable cell-directed chemotactic inhibitor recently 
described in patients with sarcoma and carcinoma (23). Failure of IgG myeloma 
samples to suppress the normal serum-mediated chemotactic system was proba- 
bly  due  to  the  intrinsic  capacity  for  IgG  to  activate  complement,  thereby 
generating complement-derived chemotactic factors. 
Analysis of IgA myeloma sera failed to show any parallel between CIA and 
the  subclass  of IgA,  light chain type,  or  the absolute  concentration of IgA, 
although when isolated IgA M  components were tested, CIA was found to be 
directly associated with these components. Sucrose density gradient centrifuga- 
tion indicated that the  majority of CIA sedimented in the  10  to  14S  range. 
Maximal inhibitory activity in these fractions implied a possible involvement of 
polymeric forms of  IgA and was consistent with both the enhanced CIA observed 
aider  56°C heating of IgA  myeloma samples  and  chemotactic  inhibition by 
colostral IgA.  Similarly, these findings appeared  to  explain the  discrepancy 
between absolute IgA M component concentration and levels of CIA. 
Further  support  for  the  involvement of polymeric  IgA  was  derived  from 
experiments that demonstrated substantial loss in IgA-mediated chemotactic 
inhibition afLer DTT sulfhydryl reduction and alkylation which results in con- 1238  SUPPREDSION  OF  CHEMOTAXIS  BY  HUMAN  IgA  MYELOMA  COMPONENTS 
FIG. 7.  Association  of  inhibitory  activity  with  exclusion  volume fractions  after  separation 
of  IgA M  component by Sephadex G-200 gel filtration.  Results of  chemotaxis with peak 
fractions  before and after  reduction alkylation and polyacrylamide  gel analysis of  these 
fractions  are shown. 
version of polymeric forms of IgA to their monomeric subunits (20). Additional 
evidence  supporting  polymeric  forms  of IgA  as  chemotactic  inhibitors  was 
obtained by Sephadex G-200 gel filtration of isolated M components.  Exclusion 
volume IgA  suppressed  PMN chemotaxis  at  low concentrations  and  lost this 
suppressive activity when samples were converted to their monomeric counter- 
parts by reduction and alkylation. Taken together, these data indicate that high 
molecular weight IgA is responsible for the majority of CIA.  It is pertinent to 
note that  although the majority of CIA was present in the  10 to 14S regions, 
some 7-8S preparations also showed CIA (Fig.  6). 
The mode of IgA suppression of PMN chemotaxis appeared to be cell directed 
since  incubation  of PMNs  with  IgA  M  components  and  subsequent  washing 
resulted in a suppressed chemotactic response. This cell-directed inhibition was 
demonstrated  to be at least partially reversible when PMNs were cultured in 
medium supplemented with fetal calf serum. Although slight effects on random 
PMN mobility were recorded with some IgA M components, such effects did not 
parallel the degree of chemotactic inhibition observed. 
IgA inhibitory activity was dependent on the Fc portion of the molecule since 
a loss in CIA was observed after pepsin digestion. In addition, data indicate that DENNIS  E.  VAN  EPPS  AND  RALPH  C.  WILLIAMS  Jr.  1239 
polymeric IgA was a  more effective inhibitor than monomeric IgA, and that 
PMNs were effected to a greater extent than monocytes. These data parallel the 
IgA binding studies reported by others (1, 24). Furthermore, three of the IgA 
preparations studied here were generously provided by Dr.  Hans Spiegelberg 
and were previously found to bind to human PMNs using radioactive binding 
techniques (1, 24). These data imply that chemotactic inhibition and IgA bind- 
ing may be mediated by similar membrane receptors. This type of chemotactic 
suppression resembles that described with IgG antibody-antigen complexes (22), 
although in the current study it was apparent that IgA was a more effective 
suppressor than IgG. Differences between IgG and IgA suppression may be the 
result of interaction with unique and separate PMN immunoglobulin receptors 
(1) or alternatively, due to the inherent ability of IgA to polymerize and form a 
more reactive complex. 
It is possible that degranulation resulting from PMN interaction with IgA (24) 
may be related to the observed chemotactic inhibition. Although degranulation 
is a potential mechanism of chemotactic inhibition, our current evidence indi- 
cating partial reversibility of the IgA inhibitory effect after prolonged incuba- 
tion is not entirely consistent with this concept. 
Data presented here support three conceivable mechanisms of IgA-mediated 
chemotactic inhibition. First, (part A, Fig. 8) chemotactic inhibition may be the 
result of interaction with the PMN IgA receptor which could directly inhibit 
PMN chemotactic receptors or suppress cellular mechanisms essential for chem- 
otaxis. A second possible mode of inhibition (part B of Fig. 8) assumes that since 
IgA may be bound to many other serum components (25-27), CIA may be the 
result of these associated components. Such inhibition could result from steric 
hindrance, direct inactivation of chemotactic factor before interaction with the 
cell membrane, or suppression of cellular functions essential for chemotaxis. 
Finally, (Fig.  8 c) interaction with the PMN may be mediated by a component 
associated with IgA which could then result in chemotactic inhibition by any of 
the previously described mechanisms. 
It is apparent from these data that IgA immunoglobulin may interact with the 
PMN and result in a  suppression of the chemotactic response.  Furthermore, 
since previous in vitro data show that IgA does not activate complement via the 
classic  complement pathway,  and  may effectively block  serum bactericidal 
activity (28), it is possible that in vivo this immunoglobulin may modify various 
aspects of the inflammatory response. 
Summary 
Sera from patients with IgA myeloma suppressed polymorphonuclear leuko- 
cyte (PMN) chemotaxis, while generally little or no suppression was observed 
with sera from patients with IgG myeloma or WaldenstrSm's macroglobuline- 
mia.  Chemotactic inhibitory activity was not limited to a  single chemotactic 
factor and was equivalent when C5a, bacterial factor, casein, or normal serum 
were used as chemotactic attractants.  No association was noted between the 
degree of inhibitory activity and the IgA subclass or light chain type. 
Chemotactic inhibitory activity was  found to  be  directly associated  with 
isolated IgA M components, and similar chemotactic suppression was noted with 1240  SUPPRESSION  OF  CHEMOTAXIS  BY  HUMAN  IgA  MYELOMA  COMPONENTS 
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Fro.  8.  Three possible mechanisms of chemotactic inhibition by IgA. 
purified preparations  of normal  human  colostral  IgA.  By  comparison,  IgA 
preparations were most effective in suppressing PMN chemotaxis and had a 
much lesser  effect on  monocyte chemotaxis.  The  mode  of IgA  chemotactic 
inhibition was cellular and at least partially reversible after a 37°C incubation 
in the absence of IgA. Some inhibition of PMN random mobility was noted with 
certain IgA preparations, although such effects did not parallel the degree of 
chemotactic inhibition. 
Fractionation of IgA myeloma sera and IgA M components by sucrose density 
gradient centrifugation showed multiple peaks of inhibitory activity in 10 to 13S 
fractions. The majority of IgA inhibitory activity was lost after pepsin digestion 
or sulfhydryl reduction and alkylation of isolated M components. When isolated 
IgA M components were fractionated on Sephadex G-200, inhibitory activity was 
associated with  the  exclusion volume and  was  abolished by  reduction and 
alkylation procedures which resulted in a conversion of polymeric IgA to mono- 
meric IgA. 
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